Servier could become the first company to bring an IDH inhibitor to market in the US for patients with myelodysplastic syndromes (MDS) next year, after the FDA started a priority review of its Tibsovo ...
Treatment options for cholangiocarcinoma remain limited, particularly once the disease becomes unresectable or metastatic, and advanced disease is associated with poor survival outcomes. Although ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results